Cape ANN Savings Bank raised its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,960 shares of the company’s stock after purchasing an additional 155 shares during the period. Cape ANN Savings Bank’s holdings in Zoetis were worth $969,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its position in Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares in the last quarter. Sarasin & Partners LLP grew its holdings in shares of Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Swedbank AB bought a new stake in shares of Zoetis during the first quarter valued at approximately $210,815,000. Marshall Wace LLP raised its stake in shares of Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after purchasing an additional 824,843 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Zoetis by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company’s stock worth $7,960,912,000 after purchasing an additional 536,477 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Stock Performance
NYSE:ZTS opened at $187.37 on Wednesday. The stock has a market capitalization of $84.89 billion, a P/E ratio of 36.10, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a 50 day moving average of $187.41 and a 200-day moving average of $175.64.
Analyst Ratings Changes
ZTS has been the topic of several analyst reports. Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $220.38.
Get Our Latest Stock Report on ZTS
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
- Five stocks we like better than Zoetis
- Insider Buying Explained: What Investors Need to Know
- Big Government Contracts Propel These 3 Defense Stocks Higher
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Powerful ETFs for Income Seekers Looking to Maximize Gains
- The Basics of Support and Resistance
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.